---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-022709"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:12:29.020691+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lixte Biotechnology appoints Jan Schellens as Chief Medical Officer, effective August 1, 2024

## Summary
- Dr. Jan Schellens named CMO effective Aug 1, 2024, succeeding James Miser who departs on July 31, 2024.
- Consulting agreement: €104,000 annual compensation, plus options for 15,000 shares at Nasdaq closing price on July 1, 2024, vesting quarterly over 3 years.
- Schellens brings 25+ years oncology experience, former CMO at Byondis B.V., board member of Dutch Medicines Evaluation Board.
- He will lead clinical trial oversight, regulatory strategy, and serve as primary medical monitor.
- Agreement provides for services 2 days per week, based in Netherlands; term until terminated by either party with 60 days' notice.

## SEC filing metadata
- accession: 0001493152-24-022709
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/0001493152-24-022709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-022709
- JSON: https://secwatch.observer/filing/0001493152-24-022709.json
- Plain text: https://secwatch.observer/filing/0001493152-24-022709.txt

## Key facts
- Executive change
  Jan Schellens was appointed as Chief Medical Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315224022709/0001493152-24-022709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.